Revelation Biosciences Statistics Share Statistics Revelation Biosciences has 1.7M
shares outstanding. The number of shares has increased by 0.04%
in one year.
Shares Outstanding 1.7M Shares Change (YoY) 0.04% Shares Change (QoQ) 0.01% Owned by Institutions (%) 0.3% Shares Floating 1.69M Failed to Deliver (FTD) Shares n/a FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 229.82K, so 13.52% of the outstanding
shares have been sold short.
Short Interest 229.82K Short % of Shares Out 13.52% Short % of Float 13.52% Short Ratio (days to cover) 2.47
Valuation Ratios The PE ratio is -0.25 and the forward
PE ratio is -0.76.
Revelation Biosciences's PEG ratio is
0.
PE Ratio -0.25 Forward PE -0.76 PS Ratio 0 Forward PS n/a PB Ratio 0.81 P/FCF Ratio -0.21 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Revelation Biosciences.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.43,
with a Debt / Equity ratio of 0.
Current Ratio 3.43 Quick Ratio 3.43 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.88M Employee Count 8 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by null% in the
last 52 weeks. The beta is -0.04, so Revelation Biosciences's
price volatility has been lower than the market average.
Beta -0.04 52-Week Price Change n/a 50-Day Moving Average 2.44 200-Day Moving Average 8.49 Relative Strength Index (RSI) 23.93 Average Volume (20 Days) n/a
Income Statement
Revenue n/a Gross Profit -27.92K Operating Income -7.97M Net Income -15.04M EBITDA -7.95M EBIT -7.97M Earnings Per Share (EPS) -87.68
Full Income Statement Balance Sheet The company has 6.5M in cash and 0 in
debt, giving a net cash position of 6.5M.
Cash & Cash Equivalents 6.5M Total Debt n/a Net Cash n/a Retained Earnings -40.51M Total Assets 5.4M Working Capital 3.79M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -18.32M
and capital expenditures -19.17K, giving a free cash flow of -18.34M.
Operating Cash Flow -18.32M Capital Expenditures -19.17K Free Cash Flow -18.34M FCF Per Share -106.94
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields REVB does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for REVB.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jul 7, 2025. It was a
backward
split with a ratio of 1:3.
Last Split Date Jul 7, 2025 Split Type backward Split Ratio 1:3
Scores Altman Z-Score -14.83 Piotroski F-Score 2
